Introduction {#Sec1}
============

Febrile neutropenia (FN) is the most common and serious complication that can occur during intensive chemotherapy for patients with hematological malignancies \[[@CR1], [@CR2]\]. Since the incidence of fungal infection can reach 24 % among patients with leukemia and the mortality from invasive aspergillosis is as high as 50 %, proper empirical antifungal therapy is essential for patients with fever persisting despite initial broad-spectrum antibacterial therapy \[[@CR3]--[@CR5]\].

For empirical use, the antifungal drug should be less toxic than amphotericin B and more effective than the azole compounds against *Aspergillus* and some *Candida* species other than *C. albicans*. Echinocandins are considered one of the most adequate compounds for empirical therapy because of their wide antifungal coverage and high efficacy against *Aspergillus* and their excellent safety profile \[[@CR6]--[@CR8]\]. Micafungin is a novel echinocandin that has shown activity against the *Candida* and *Aspergillus* species by inhibiting the synthesis of 1,3-β-[d]{.smallcaps}-glucan, an essential component of the fungal cell wall \[[@CR9]\]. Micafungin has shown its possible efficacy and safety as empirical therapy for febrile neutropenic patients in non-randomized studies \[[@CR10]--[@CR13]\]. In addition, micafungin may have an advantage over azole-resistant *Candida* and *Aspergillus* species \[[@CR14], [@CR15]\]. In Korea, itraconazole has been the only drug approved for empirical antifungal therapy since 2005 despite increasing demands for new antifungal empirical therapy. However, there has been no controlled study comparing other antifungal agents with itraconazole for empirical therapy among Koreans. Thus, in this study, we prospectively compared clinical outcomes of micafungin with intravenous itraconazole for empirical therapy in febrile neutropenia following anticancer chemotherapy for hematological disorders.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

This prospective randomized study was conducted from December 2012 through February 2014 at seven sites in South Korea. This study was designed as a non-inferiority test to document clinical outcomes of micafungin compared to those of itraconazole. The institutional review board of each participating institution approved this study design, and this study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before enrollment. The study protocol was registered with the National Institutes of Health clinical trial registry at [www.clinicaltrials.gov](http://www.clinicaltrials.gov/) (\#NCT01344681).

Adult patients (age ≥ 18 years) were included if they had grade 4 neutropenia (absolute neutrophil count ≤500/μL) and high fever (≥38.4 °C at any time or ≥38.0 °C for 1 h by oral temperature) resulting from intensive anticancer chemotherapy for acute leukemia, highly aggressive lymphoma (Burkitt lymphoma, lymphoblastic lymphoma), or other hematological malignancies. To be eligible, patients had to have persistent high fever against proper broad-spectrum intravenous antibiotics for at least 72 h.

When patients met all the inclusion criteria, they were randomly assigned, in a 1:1 ratio by block randomization, to receive micafungin or itraconazole. Randomization was performed according to disease, patient age, sex, and risk stratification (remission induction or salvage therapy, high risk; consolidation, low risk). Subjects were automatically assigned by a pre-made random code with a Web-based electronic system. The randomized block design applied for the random code with risk stratification. Administration of oral antifungal agents for prophylaxis prior to the study was allowed.

Micafungin (Mycamine®, Astellas Pharma Tech Co., Ltd. Takaoka City, Japan) was administrated intravenously in normal saline at a dose of 100 mg over 60 min once daily. Itraconazole (Sporanox®, Janssen-Cilag Ltd., Buckinghamshire, England) was administrated intravenously at a dose of 200 mg twice daily for 2 days and then 200 mg once daily for 12 days. The minimum administration duration of the study drugs was 5 days. When the patients recovered from granulocytic nadir without fever, the empirical therapy was discontinued and treatment was considered to have been completed. Persistent high fever for 7 days after initiation of the antifungal drug was considered treatment failure, and a change in the assigned antifungal drug was allowed based on the individual decision of each investigator.

Efficacy and safety {#Sec4}
-------------------

The primary end point was the overall success rate. Therapy was considered successful if the patient met all of the following criteria: (1) did not have a breakthrough invasive fungal infection (IFI); (2) survived for 7 days after therapy ended; (3) no premature discontinuation because of adverse events or lack of effects; (4) defervescence during granulocytic nadir; and (5) successful treatment of any baseline fungal infection. The breakthrough IFI was defined as proven or probable IFI with onset of symptoms of an IFI on day 3 or later after initiation of antifungal therapy following revised EORTC/MSG criteria \[[@CR16]\]. These five components were used to determine the overall response rate \[[@CR17]\].

The secondary end points were duration of fever, duration of febrile neutropenia, duration of hospital stay, and overall survival rate (OS). Toxicity profiles including physical findings and laboratory data were recorded and followed up until they were resolved using the National Cancer Institute Common Toxicity Criteria version 3.0.

Statistical analysis {#Sec5}
--------------------

Analysis was based on an intention-to-treat approach from all patients who underwent randomization. The non-inferiority of micafungin in comparison with itraconazole was assessed and the inferiority margin was 10 %. The sample size was calculated from previous independent studies for empirical micafungin and itraconazole that had already shown response rates as 61.7 and 47 %, respectively \[[@CR13], [@CR18]\]. A sample size of 154 patients was achieved with the type 1 and type 2 errors of 0.025 and 0.8, respectively. The overall response rate of the antifungal agents was analyzed by Fisher's exact test. Overall survival, duration of fever, and duration of hospital stay were assessed with the chi-square and log-rank tests. The two-sided *t* test was applied for patient characteristics, and a *p* value of less than 0.05 was considered to indicate statistical significance.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

A total of 153 patients were randomly assigned to the micafungin (*n* = 77) or itraconazole group (*n* = 76). Among them, 148 patients were treated with the study drugs (73 patients in the micafungin group and 75 patients in the itraconazole group). The completion rates of treatment with micafungin and itraconazole were 78.1 % (57/73) and 78.7 % (59/75), respectively (Fig. [1](#Fig1){ref-type="fig"}). All of the patients were native Koreans who received intensive anticancer chemotherapy for various hematological malignancies, mainly for acute leukemia. Sixty-three patients (86.3 %) were high-risk (remission induction or salvage) in the micafungin group and 64 patients (85.3 %) in the itraconazole group. Prophylactic antifungal therapy was used in 50.7 % of the patients in the micafungin group (fluconazole in 32 patients and itraconazole in 5) and 52.0 % in the itraconazole group (fluconazole in 34 patients and itraconazole in 5) before the initiation of the study drug. The median treatment duration of the study drug was 8 days in both groups. Patient characteristics including gender, age, diagnosis, and risk stratification were balanced (Table [1](#Tab1){ref-type="table"}).Fig. 1Flowchart of the studyTable 1Patient characteristicsMicafungin group (*n* = 73)Itraconazole group (*n* = 75)*p* valueGender, *n*Male42400.624Female3135Age, yearsMean (range)49 (20--85)49 (20--78)0.749Diagnosis, *n* (%)AML45 (61.6)43 (57.3)0.926ALL19 (26.0)20 (26.6)NHL5 (6.8)6 (8.0)Burkitt's22Lymphoblastic34Others4 (5.4)6 (8.0)MDS34CMML10MM02Underlying infection (other than fungal), *n* (%)Total30 (41.0)22 (29.3)0.169Bacterial1713Viral139Treatment setting, *n* (%)Remission44 (60.2)41 (54.6)0.629Salvage17 (23.3)23 (30.7)Consolidation12 (16.4)11 (14.7)Antifungal prophylaxis, *n* (%)37 (50.7)39 (52.0)0.869Neutropenia duration, daysMedian (range)16 (4--63)15 (5--26)0.676Treatment duration, daysMedian (range)8 (3--20)8 (1--18)0.452*AML* acute myeloid leukemia, *ALL* acute lymphoblastic leukemia, *NHL* non-Hodgkin lymphoma, *MDS* myelodysplastic syndrome, *CMML* chronic myelomonocytic leukemia

Success rate {#Sec8}
------------

The outcomes of the five composite parameters are shown in Table [2](#Tab2){ref-type="table"}. There was no significant difference in each composite parameter between the two groups. A total of 16 patients had baseline fungal infection documented within 2 days from the initiation of study drugs (7 patients in the micafungin group, 9 patients in the itraconazole group). Four out of 7 patients (57.1 %) in the micafungin group and 5 out of 9 patients (55.6 %) in the itraconazole group have their documented fungal infection resolved with antifungal therapy during the study. Documented organisms and response are presented in Table [3](#Tab3){ref-type="table"}. Breakthrough IFI occurred in 3 patients in the micafungin group with one proven IFI of *Candida* spp. and 2 probable cases. In the itraconazole group, there were two proven IFI of *Aspergillus* spp. and 3 probable cases. The overall success rates of micafungin and itraconazole were 64.4 and 57.3 %, respectively. The difference in the success rates (7.1 %) was not statistically significant (*p* = 0.404). Thus, these results satisfied non-inferiority criteria.Table 2Overall success rateParameterMicafungin (%)Itraconazole (%)*p* valueOverall success rate47/73 (64.4)43/75 (57.2)0.404 1. No breakthrough fungal infection^a^70/73 (95.9)70/75 (93.3)0.719 2. Survived for at least 7 days after the end of therapy67/73 (91.8)67/75 (89.3)0.780 3. No premature discontinuation for lack of efficacy or toxicity50/73 (68.5)49/75 (65.3)0.729 4. Resolution of fever during neutropenia49/73 (67.1)45/75 (73.3)0.473 5. Resolution of baseline fungal infection4/7 (57.1)5/9 (55.6)1.000^a^Breakthrough fungal infection: proven in 3 (*Aspergillus* spp. 2, *Candida* spp. 1) and probable in 5Table 3The treatment outcome of baseline fungal infectionStudy groupDocumented fungiResolutionResolution rateMicafungin*Aspergillus flavus*\
*Candida albicans*\
*Candida tropicalis*\
*Candida* spp.\
*Trichosporon asahii*1/1\
2/2\
1/2\
0/1\
0/157.1 %Itraconazole*Aspergillus* spp.\
*Candida albicans*\
*Candida tropicalis*\
*Candida* spp.1/3\
2/4\
1/1\
1/155.6 %All of the fungi were documented within 2 days of the initiation of study drugs

Defervescence, hospital stay, and overall survival {#Sec9}
--------------------------------------------------

The median duration of fever in the micafungin and itraconazole groups was 6.0 (95 % CI, 5--7) and 7.0 (95 % CI, 5--9) days, and the duration of fever was different between the two groups (*p* = 0.014) (Fig. [2a](#Fig2){ref-type="fig"}). The median duration of hospital stay in the micafungin group and itraconazole group was 22 (95 % CI, 19--25) and 27 (95 % CI, 25--29) days, and the duration of hospitalization was significantly lower in the micafungin group (*p* = 0.033) (Fig. [2b](#Fig2){ref-type="fig"}). The median OS in the micafungin group and itraconazole group was 12.77 (95 % CI, 8.92--16.62) and 9.27 (95 % CI, 5.27--13.27) months, respectively (*p* = NS). In responding patients, the median duration of drug delivery was 9.0 (95 % CI, 7--11) and 11.0 (95 % CI, 8--14) days in the micafungin and itraconazole group, respectively (*p* = NS).Fig. 2Duration of fever (**a**) and hospital stay (**b**)

Adverse events {#Sec10}
--------------

All 153 patients who were in the intention-to-treat population were included in the safety evaluation. The incidence and severity of adverse events were similar between the two groups (Table [4](#Tab4){ref-type="table"}). Grade 3 hyperbilirubinemia, a well-known common adverse event of antifungal drugs, was observed in 2 and 7 patients in the micafungin and itraconazole group, respectively. Each case of atrial fibrillation and anaphylaxis was observed in the micafungin group, and the events were controlled with medications. Nine patients in the micafungin group (12.3 %) and 16 patients in the itraconazole group (21.3 %) discontinued study drugs prematurely because of adverse events. However, there was no adverse event-related death in both groups and 3 and 4 patients died of fatal infections in the micafungin and itraconazole group, respectively.Table 4Adverse eventsAdverse eventsMicafungin (*n* = 73)Itraconazole (*n* = 75)All grades (*n*)Grade III--IV (*n*)All grades (*n*)Grade III--IV (*n*)Hyperbilirubinemia\
Elevation of transaminase level\
Electrolyte imbalance\
Atrial fibrillation\
Anaphylaxis\
Delirium\
Insomnia\
Skin rash10\
5\
18\
1\
1\
3\
4\
92\
2\
1\
1\
1\
0\
0\
011\
19\
16\
0\
0\
2\
1\
57\
4\
2\
0\
0\
0\
0\
0Total51114417Probability of grade 3 or more severe adverse events was not different between the two groups. Each case of atrial fibrillation and anaphylaxis occurred in the micafungin group, which should be reminded prudently despite the fact that the events were well controlled with medications

Discussion {#Sec11}
==========

This randomized, multicenter trial has shown that empirical micafungin is as effective as itraconazole for patients with febrile neutropenia. Micafungin compares favorably with itraconazole in terms of overall success rates and toxicity profiles. Theoretically, the echinocandins have advantages over the azole or polyene compounds as empirical therapy because of their wide coverage and high efficacy against invasive aspergillosis \[[@CR7], [@CR8]\]. The efficacy and safety of the echinocandins as empirical antifungal therapy were demonstrated with caspofungin by Walsh et al. \[[@CR17]\]. When compared to liposomal amphotericin B, caspofungin showed favorable efficacy and a better toxicity profile and tolerance. Micafungin is another new echinocandin that has considerable efficacy and a notable toxicity profile \[[@CR11], [@CR12], [@CR19], [@CR20]\]. We previously investigated the possible efficacy and safety of micafungin as an empirical therapy in febrile neutropenia with a small observational study \[[@CR13]\]. However, there has been no randomized study to compare micafungin with other agents as empirical therapy. As far as we know, this is the first randomized study of micafungin as empirical therapy in febrile neutropenia. Since itraconazole has been the only drug allowed for empirical therapy in Korea since 2005, we had to compare micafungin with itraconazole in this study.

In this study, the overall success rate evaluated with five composite scores was somewhat higher (64.4 % for the micafungin group and 57.2 % for the itraconazole group) than that of previous studies on empirical therapy with liposomal amphotericin, voriconazole, and caspofungin \[[@CR17], [@CR21], [@CR22]\]. In this study, the patients started empirical antifungal drugs earlier than those in previous studies when they had sustained fever more than 72 h despite proper antibiotics therapy, whereas 96--120 h in other studies. Another possible explanation is that the patients undergoing hematopoietic stem cell transplantation (HSCT) were not included in this study unlike other empirical trials, since micafungin was allowed to be used as prophylactic therapy for HSCT in Korea.

Breakthrough fungal infection occurred in 3 patients (4 %) in the micafungin group. One patient was proven to have systemic *Candida* infection. Although micafungin has potent activity against *Candida* spp. and *Aspergillus* spp., recent research has shown that breakthrough IFI occurred most commonly due to *Candida* spp. for high minimum inhibitory concentration and/or relative insensitivity to echinocandins \[[@CR23]\]. Thus, systemic candidemia should be considered when the patients show clinical aggravation despite micafungin treatment.

Another strength of this study is that the study population consists of homogeneous patients undergoing intensive chemotherapy for hematological malignancies where anticipated mortality from IFIs is the highest. Although some studies pursued a preemptive strategy with recent advances of sensitive mycological tests and imaging techniques \[[@CR24], [@CR25]\], the most effective strategy in preventing or treating invasive fungal disease in febrile neutropenia is still under debate. Since the mortality from IFIs is considerable in patients with acute leukemia suffering from febrile neutropenia, especially while undergoing induction chemotherapy, empirical therapy is still widely accepted in this clinical setting \[[@CR26]\]. This study showed the efficacy of micafungin as an empirical therapy option in this high-risk population.

Duration of hospital stay was adopted as an indication of the overall effectiveness of empirical antifungal treatment. It could be a good surrogate for the combined results of treatment success, adverse effects, and other clinical aspects. The duration of neutropenia was not different between the two groups, and duration of fever was only modestly shorter in the micafungin group. However, the duration of hospitalization was shorter in the micafungin group by median 5 days (22 vs. 27 days, *p* = 0.033). This may benefit patients because it allows treatment to progress to the next step in a timely manner and dose intensity can be maintained throughout the entire treatment while treatment costs can also be decreased. Although not proven in this study, this may be translated to a better long-term treatment outcome. Considering the shorter hospital stay, micafungin seems to have advantages over itraconazole despite no significant difference in the overall success rate by a composite score between the two groups.

In summary, micafungin was effective as empirical therapy in sustained fever and neutropenia with acceptable toxicity profiles in comparison with itraconazole. Additionally, it significantly decreased the duration of hospitalization when compared to itraconazole. Among available antifungal agents, micafungin could be a favorable option for empirical antifungal treatment in febrile neutropenia.

The institutional review board of each participating institution approved this study design, and this study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before enrollment. The study protocol was registered with the National Institutes of Health clinical trial registry at [www.clinicaltrials.gov](http://www.clinicaltrials.gov/) (\#NCT01344681).
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